Scandinavian ChemoTech's co-founder Göran Hellers has passed away
It is with great sadness that we announce that the Company's co-founder, former board member and our friend, Göran Hellers, has died after a short illness.
“With great sadness in my heart, I have today received information that my friend and co-founder of ChemoTech has passed away. Since we met 10 years ago, Dr Göran has been an extremely knowledgeable and driven colleague who, alongside me, launched the first generation of electroporation in Asia, Africa and South America. It was during those years that Göran and I saw the shortcomings of the older electroporation method and realized that there was considerable room for innovation, which resulted in the development of our TSE technology. There are few people I have met who have had the drive and commitment that Göran had. He leaves a big void behind and our thoughts go out primarily to his wife, children and grandchildren.” -says CEO and friend Mohan Frick
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
